A Study of the Effectiveness in Patients With Gastric or Gastroesophageal Junction Cancer With Nivolumab by Itself or in Combination With Ipilimumab and in Patients With Esophageal Cancer With Combination of Nivolumab and Ipilimumab.

Condition:   Various Advanced Cancer
Interventions:   Drug: Nivolumab monotherapy;   Drug: Nivolumab + Ipilimumab followed by Nivolumab monotherapy;   Drug: Nivolumab + Ipilimumab
Sponsors:   Bristol-Myers Squibb;   Ono Pharmaceutical Co. Ltd
Not yet recruiting - verified May 2017

http://ift.tt/2pYosXT